Programming - Hypertension Scientific Sessions 2021

2021 Programming Schedule

3 Days of programming beginning 10:00 a.m. Central Time Monday

Monday, September 27 10:00 a.m. Central Time

We are excited to announce the conference will open with the recipient of the 2019 Nobel Prize in Physiology or Medicine:

Gregg L. Semenza, MD, PhD


Gregg L. Semenza, MD, PhD, Director, Vascular Program, Institute for Cell Engineering

Professor of Genetic Medicine, Johns Hopkins University, 2019 Nobel Prize in Physiology or Medicine

Presenting: Hypoxia-Inducible Factors in Physiology and Medicine.

Clinical programming all three days will include sessions on:

  • Hypertension Management Through the Lifespan: Children/Adolescence, Middle Age, Older Adults.
  • Equity in Hypertension Control: Role of Clinicians, Communities, and Health Policy
  • Managing BP Beyond the Physician Room: Lifestyle Interventions, Social Support, and Home Blood Pressure Monitoring
  • Beyond ABCD... Outpatient Management of Resistant Hypertension.
  • Managing Hypertension Through Telemedicine: Billing for Home Blood Pressure Monitoring and Virtual Communication
  • Landscape of Hypertension Clinical Trials and Future Directions for Research
  • Team-Based Care to Improve BP Control: What is the Dream Team?
     

Hypertension Trainee Advocacy committee oral abstract track

This track will highlight science submitted by early career, junior investigators. Oral sessions will be offered all three days!

All trainees with abstracts chosen for platform oral presentations will receive a Trainee Advisory Committee (TAC) Research Recognition Award covering member registration to the conference ($99 value).


Recent Advances Programming

  • Council on Kidney in Cardiovascular Disease Symposium: Abundant Protein with Ample Evidence- Role of Uromodulin in Hypertension, Kidney Disease, and Inflammation
  • Council on Hypertension Symposium: Single Cell Epigenomics and Transcriptomics
     

Award Lectures with Integrated Abstract Presentations

Monday, September 27

Monday Programming
Time Event
10:00 a.m. CDT  

Session 1:

Opening remarks and Keynote

Keynote: Hypoxia-Inducible Factors in Physiology and Medicine – Dr. Gregg L. Semenza, MD, PhD

11:15 a.m. CDT  

Session 2A
Council on Kidney in Cardiovascular Disease Symposium: Abundant Protein with Ample Evidence- Role of Uromodulin in Hypertension, Kidney Disease, and Inflammation

Session 2B
Trainee Advocacy Committee (TAC) Oral Abstract Presentations

Session 2C
Clinical Programming

12:30 p.m. CDT  

Session 3A
Council on Hypertension Symposium: Single Cell Epigenomics and Transcriptomics

Session 3B
Trainee Advocacy Committee (TAC) Oral Abstract Presentations

Session 3C
Clinical Programming

2:00–4:00 p.m. CDT  

Moderated Poster Sessions

“Meet Dr Semenza” special networking session

Trainee Advocacy sessions and other networking and special sessions

Tuesday, September 28

Tuesday Programming
Time Event
10:00 a.m. CDT  

Session 4A
The Excellence Award for Hypertension Research Lecture

The Arthur C. Corcoran Memorial Lecture

Session 4B
Trainee Advocacy Committee (TAC) Oral Abstract Presentations

Session 4C
Clinical Programming

11:15 a.m. CDT  

Session 5A
The Donald Seldin Lecture, followed by selected oral abstract presentations

Session 5B
Trainee Advocacy Committee (TAC) Oral Abstract Presentations

Session 5C
Clinical Programming

12:30 PM CDT  

Session 6A
The Lewis K. Dahl Memorial Lecture, followed by selected oral abstract presentations

Session 6B
Trainee Advocacy Committee (TAC) Oral Abstract Presentations

Session 6C
Clinical Programming

2:00–4:00 p.m. CDT  

Moderated Poster Sessions

Trainee Advocacy sessions and other networking and special sessions

Wednesday, September 29

Wednesday Programming
Time Event
10:00 a.m. CDT  

Session 7A
The Harriet Dustan Award Lecture, followed by selected oral abstract presentations

Session 7B
Trainee Advocacy Committee (TAC) Oral Abstract Presentations

Session 7C
Clinical Programming

11:15 a.m. CDT  

Session 8A
The Mid-Career Award for Research Excellence, followed by selected oral abstract presentations

Session 8B
Trainee Advocacy Committee (TAC) Oral Abstract Presentations

Session 8C
Clinical Programming

12:30 PM CDT  

Session 9A
The Harry Goldblatt Award for Early Career Investigators, followed by selected oral abstract presentations

Session 9B
Trainee Advocacy Committee (TAC) Oral Abstract Presentations

Session 9C
Clinical Programming

2:00–4:00 p.m. CDT  

Moderated Poster Sessions

Trainee Advocacy sessions and other networking and special sessions

Programming will also include

  • The Stephanie Watts Career Development Award Finalists
  • The British-Irish Hypertension Society Young Investigator Award
  • The High Blood Pressure Research Council of Australia Award
  • Live Moderated Poster Sessions
  • Live Hypertension Journal Case Study Session
  • Live Networking events

What's new for 2021

We know this has been an exceptionally challenging year in so many ways. We want to recognize all the research and clinical work that has been performed during this difficult time. Therefore, attendees can expect that the program will be dedicated to important and innovative clinical topics in hypertension as well as research performed by our members and attendees. The latter will primarily include abstract presentations.

Expectations of the program

  • COH and KCVD Awards Program
  • Keynote Lecture 
  • Clinical science and primary care sessions 
  • Symposia on hot topics 
  • Basic and translational science weighted toward presentations derived from submitted abstracts

About This Meeting

Hypertension 2021 Scientific Sessions, focusing on recent advances in basic and clinical research on hypertension, is considered the premier scientific meeting on the subject in the world. A collaborative effort between the Council on Hypertension and the Council on the Kidney in Cardiovascular Disease, the science submitted to this conference continues to bring us the most up to date developments on our understanding of: the causes of hypertension; its relationship to stroke, cardiac disease and kidney dysfunction; and the most effective means for detecting, evaluating and treating high blood pressure across diverse populations.

Target Audience

The conference is designed to benefit research scientists, clinicians, and other healthcare professionals in the fields of hypertension research, cardiology, nephrology, endocrinology and related disciplines.

Learning Objectives

  1. Discuss changes to the AHA/ACC guidelines for the management of hypertension and their clinical implications.
  2. Describe opportunities to improve blood pressure measurement in the clinical setting to provide more accurate results.
  3. Identify immune and inflammatory mechanisms that contribute to the development of hypertension and hypertension-related end-organ damage and discuss the research and clinical implications.
  4. Educate participants about medical approaches for the management of comorbid obesity in patients with hypertension.
  5. Describe new and emerging strategies for treating resistant hypertension.
  6. Describe participants on the impact of value-based reimbursement on hypertension management and identify opportunities to improve its management.